1
|
Koumourtzis MR, Georgakopoulos I, Lampadaki K, Vaiopoulos A, Marinos L, Platoni K, Mpouhla A, Kypraiou E, Nikolaou V, Tsirigotis P, Kouloulias V, Pappa V, Stratigos A. Low vs. high-dose total skin electron beam therapy for mycosis fungoides: efficacy and safety analysis. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00644-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
2
|
Papadavid E, Koumourtzis M, Nikolaou V, Lampadaki K, Marinos L, Patsatsi A, Georgiou E, Dalamaga M, Stratigos A. Chlormethine gel is effective for the treatment of skin lesions in patients with early- and late-stage mycosis fungoides in clinical practice. J Eur Acad Dermatol Venereol 2022; 36:1751-1757. [PMID: 35470483 DOI: 10.1111/jdv.18183] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Accepted: 04/19/2022] [Indexed: 11/26/2022]
Abstract
BACKGROUND Chlormethine gel is a skin-directed therapy used for patients with mycosis fungoides (MF) that showed a favorable risk/benefit profile in a randomized clinical trial. Currently, data on chlormethine gel use in real-world settings are limited. OBJECTIVES To assess safety and efficacy of chlormethine gel treatment in patients treated during daily clinical practice, and investigate associations between response and disease stage, lesion type, mono- or combination therapy, and occurrence of dermatitis. METHODS Clinical data from patients using chlormethine gel from three sites in Greece were analyzed. Efficacy was assessed through modified Severity-Weighted Assessment Tool (mSWAT) scores. Safety assessments included analysis of the occurrence and severity of dermatitis. The Skindex-29 questionnaire was used for quality-of-life assessments. RESULTS Fifty-eight patients were included. The overall response rate (ORR) increased from 37.9% at month 1 to 80.8% at month 9. For 64.2% of patients, response was maintained for at least 4 months (ORR4). At month 3, a higher ORR was seen for patients with patches (69.7%) than patients with plaques/tumors (both 15.2%). A higher ORR4 was observed for patients with early- vs late-stage disease (71.4% vs 36.4%) and patients on mono- vs combination therapy (75% vs 47.6%). Dermatitis was observed in the majority of patients (72.4%), but the presence or severity of dermatitis was not directly correlated with treatment response. Both mSWAT and Skindex-29 scores decreased significantly during treatment, and changes in these scores from baseline to month 6 showed a positive correlation (r = 0.55, P = 0.026). CONCLUSIONS Chlormethine gel was effective for treatment of skin lesions in patients with early- and late-stage MF in clinical practice. Response rates increased over time, indicating that continued treatment with the gel is important. Dermatitis may be managed by reducing the treatment frequency; the occurrence of dermatitis did not affect the response to treatment.
Collapse
Affiliation(s)
- E Papadavid
- 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece
| | - M Koumourtzis
- 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece
| | - V Nikolaou
- 1st Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University of Athens Medical School, "Andreas Sygros" Hospital for Skin Diseases, Athens, Greece
| | - K Lampadaki
- 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece
| | - L Marinos
- Department of Hematopathology, Evangelismos General Hospital, Athens, Greece
| | - A Patsatsi
- 2nd Dermatology Department, Aristotle University, School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece
| | - E Georgiou
- 2nd Dermatology Department, Aristotle University, School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece
| | - M Dalamaga
- Department of Biological Chemistry, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - A Stratigos
- 1st Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University of Athens Medical School, "Andreas Sygros" Hospital for Skin Diseases, Athens, Greece
| |
Collapse
|
3
|
Panou E, Nikolaou V, Marinos L, Kallambou S, Sidiropoulou P, Gerochristou M, Stratigos A. Recurrence of cutaneous T-cell lymphoma post viral vector COVID-19 vaccination. J Eur Acad Dermatol Venereol 2022; 36:e91-e93. [PMID: 34628691 PMCID: PMC9088536 DOI: 10.1111/jdv.17736] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- E. Panou
- 1st Dermatology DepartmentAndreas Syggros Hospital for Skin DiseasesNational & Kapodestrian University of Athens Medical SchooolAthensGreece
| | - V. Nikolaou
- 1st Dermatology DepartmentAndreas Syggros Hospital for Skin DiseasesNational & Kapodestrian University of Athens Medical SchooolAthensGreece
| | - L. Marinos
- Department of HemopathologyEvangelismos HospitalAthensGreece
| | - S. Kallambou
- 1st Dermatology DepartmentAndreas Syggros Hospital for Skin DiseasesNational & Kapodestrian University of Athens Medical SchooolAthensGreece
| | - P. Sidiropoulou
- 1st Dermatology DepartmentAndreas Syggros Hospital for Skin DiseasesNational & Kapodestrian University of Athens Medical SchooolAthensGreece
| | - M. Gerochristou
- 1st Dermatology DepartmentAndreas Syggros Hospital for Skin DiseasesNational & Kapodestrian University of Athens Medical SchooolAthensGreece
| | - A. Stratigos
- 1st Dermatology DepartmentAndreas Syggros Hospital for Skin DiseasesNational & Kapodestrian University of Athens Medical SchooolAthensGreece
| |
Collapse
|
4
|
Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz-Romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Child F, Whittaker S, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram-Wolff C, Battistella M, Alberti-Violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot-Barry M, Pham-Ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel-Kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon-Pennamen MD, Battistella M, Climent F, Gonzalez-Barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots AM, Hauben E, Bervoets A, Woei-A-Jin FJSH, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, McKay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches JA, Miyashiro D, Akilov O, McCann S, Sahi H, Damasco FM, Querfeld C, Folkes A, Bur C, Klemke CD, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 2019; 181:350-357. [PMID: 30267549 DOI: 10.1111/bjd.17258] [Citation(s) in RCA: 112] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/25/2018] [Indexed: 12/16/2022]
Abstract
BACKGROUND Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study is a web-based data collection system for early-stage MF with legal data-sharing agreements permitting international collaboration in a rare cancer with complex pathology. Clinicopathological data must be 100% complete and in-built intelligence in the database system ensures accurate staging. OBJECTIVES To develop a prognostic index for MF. METHODS Predefined datasets for clinical, haematological, radiological, immunohistochemical, genotypic, treatment and quality of life are collected at first diagnosis of MF and annually to test against survival. Biobanked tissue samples are recorded within a Federated Biobank for translational studies. RESULTS In total, 430 patients were enrolled from 29 centres in 15 countries spanning five continents. Altogether, 348 were confirmed as having early-stage MF at central review. The majority had classical MF (81·6%) with a CD4 phenotype (88·2%). Folliculotropic MF was diagnosed in 17·8%. Most presented with stage I (IA: 49·4%; IB: 42·8%), but 7·8% presented with enlarged lymph nodes (stage IIA). A diagnostic delay between first symptom development and initial diagnosis was frequent [85·6%; median delay 36 months (interquartile range 12-90)]. This highlights the difficulties in accurate diagnosis, which includes lack of a singular diagnostic test for MF. CONCLUSIONS This confirmed early-stage MF cohort is being followed-up to identify prognostic factors, which may allow better management and improve survival by identifying patients at risk of disease progression. This study design is a useful model for collaboration in other rare diseases, especially where pathological diagnosis can be complex.
Collapse
Affiliation(s)
- J J Scarisbrick
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
- Member of the UK Cutaneous Lymphoma Group
| | - P Quaglino
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - H M Prince
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Papadavid
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Hodak
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - M Bagot
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - O Servitje
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Berti
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - P Ortiz-Romero
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Stadler
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - A Patsatsi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Knobler
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Guenova
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - F Child
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - S Whittaker
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
- Member of the UK Cutaneous Lymphoma Group
| | - V Nikolaou
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Tomasini
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - I Amitay
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - H Prag Naveh
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Ram-Wolff
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Battistella
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - S Alberti-Violetti
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Stranzenbach
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - V Gargallo
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - C Muniesa
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - T Koletsa
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - C Jonak
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - S Porkert
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - C Mitteldorf
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - T Estrach
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Combalia
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Marschalko
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - J Csomor
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Szepesi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Cozzio
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Dummer
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - N Pimpinelli
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - V Grandi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Beylot-Barry
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Pham-Ledard
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Wobser
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Geissinger
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - U Wehkamp
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - M Weichenthal
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Cowan
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - E Parry
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - J Harris
- Member of the UK Cutaneous Lymphoma Group
| | - R Wachsmuth
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - D Turner
- Member of the UK Cutaneous Lymphoma Group
| | - A Bates
- Member of the UK Cutaneous Lymphoma Group
| | - E Healy
- Member of the UK Cutaneous Lymphoma Group
| | - F Trautinger
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - J Latzka
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - J Yoo
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - B Vydianath
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
| | - R Amel-Kashipaz
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
| | - L Marinos
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Oikonomidi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Stratigos
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M-D Vignon-Pennamen
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Battistella
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - F Climent
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Gonzalez-Barca
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Georgiou
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Senetta
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - P Zinzani
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - L Vakeva
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Ranki
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A-M Busschots
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Hauben
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Bervoets
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - F J S H Woei-A-Jin
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Matin
- Member of the UK Cutaneous Lymphoma Group
| | - G Collins
- Member of the UK Cutaneous Lymphoma Group
| | | | - J Frew
- Member of the UK Cutaneous Lymphoma Group
| | - M Bayne
- Member of the UK Cutaneous Lymphoma Group
| | - G Dunnill
- Member of the UK Cutaneous Lymphoma Group
| | - P McKay
- Member of the UK Cutaneous Lymphoma Group
| | | | - R Azurdia
- Member of the UK Cutaneous Lymphoma Group
| | - K Benstead
- Member of the UK Cutaneous Lymphoma Group
| | - R Twigger
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - K Rieger
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Brown
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - J A Sanches
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - D Miyashiro
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - O Akilov
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - S McCann
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - H Sahi
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - F M Damasco
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Querfeld
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - A Folkes
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Bur
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C-D Klemke
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - P Enz
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Pujol
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - K Quint
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - L Geskin
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Hong
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - F Evison
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
| | - M Vermeer
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - L Cerroni
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - W Kempf
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - Y Kim
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Willemze
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| |
Collapse
|
5
|
Papadavid E, Kapniari E, Marinos L, Nikolaou V, Oikonomidi A, Georgakopoulos J, Stratigos A, Kouloulias V, Pappa V. Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients. J Eur Acad Dermatol Venereol 2019; 33:e223-e225. [PMID: 30821007 DOI: 10.1111/jdv.15409] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- E Papadavid
- National and Kapodistrian Univeristy of Athens, 2nd Department of Dermatology Venereology, Attikon General University Hospital, Athens, Greece
| | - E Kapniari
- National and Kapodistrian Univeristy of Athens, 2nd Department of Dermatology Venereology, Attikon General University Hospital, Athens, Greece
| | - L Marinos
- Hemato Pathology Department, Evaggelismos General Hospital, Athens, Greece
| | - V Nikolaou
- National and Kapodistrian University of Athens, 1st Department of Dermatology Venereology, Syggros Hospital, Athens, Greece
| | - A Oikonomidi
- National and Kapodistrian University of Athens, 1st Department of Dermatology Venereology, Syggros Hospital, Athens, Greece
| | - J Georgakopoulos
- National and Kapodistrian University of Athens, 2nd Department of Radiology, Radiology Oncology, Attikon General University Hospital, Athens, Greece
| | - A Stratigos
- National and Kapodistrian University of Athens, 1st Department of Dermatology Venereology, Syggros Hospital, Athens, Greece
| | - V Kouloulias
- National and Kapodistrian University of Athens, 2nd Department of Radiology, Radiology Oncology, Attikon General University Hospital, Athens, Greece
| | - V Pappa
- National and Kapodistrian University of Athens, 2nd Propedeutic Department, Hematology Unit, Attikon General University Hospital, Athens, Greece
| |
Collapse
|
6
|
Anagnostopoulos I, Lagou S, Papatheodoridi M, Marinos L, Karakatsanis S, Syrigos KN. A rare case of bone marrow BCG-itis responding to second-line anti-tuberculosis treatment. Int J Tuberc Lung Dis 2019; 23:119-120. [PMID: 30674384 DOI: 10.5588/ijtld.18.0576] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- I Anagnostopoulos
- 3rd Department of Medicine, GNA 'Sotiria', National and Kapodistrian University of Athens, Athens
| | - S Lagou
- 3rd Department of Medicine, GNA 'Sotiria', National and Kapodistrian University of Athens, Athens
| | - M Papatheodoridi
- 3rd Department of Medicine, GNA 'Sotiria', National and Kapodistrian University of Athens, Athens
| | - L Marinos
- Hematopathology Department, Evangelismos General Hospital, Athens, Greece, ; ,
| | - S Karakatsanis
- 3rd Department of Medicine, GNA 'Sotiria', National and Kapodistrian University of Athens, Athens
| | - K N Syrigos
- 3rd Department of Medicine, GNA 'Sotiria', National and Kapodistrian University of Athens, Athens
| |
Collapse
|
7
|
Nikolaou V, Sidiropoulou P, Papanikou S, Marinos L, Voudouri D, Rigopoulos D, Chasapi V, Trafalis D, Stratigos A. Folliculotropic mycosis fungoides in the setting of nivolumab immunotherapy. Eur J Cancer 2019. [DOI: 10.1016/s0959-8049(19)30630-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Nikolaou V, Iliakis T, Marinos L, Economidi A, Panayiotidis P, Rigopoulos D, Stratigos AJ. Brentuximab induced CD30 + cutaneous lymphoma responded to anti-PD1 treatment. J Eur Acad Dermatol Venereol 2018; 33:e147-e148. [PMID: 30520137 DOI: 10.1111/jdv.15378] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- V Nikolaou
- Dermatology Department, Cutaneous Lymphoma Clinic, Medical School, "A. Sygros" Hospital for Skin Diseases, National & Kapodestrian University of Athens, Athens, 16121, Greece
| | - T Iliakis
- Hematology Unit, 1st Propedeutic Department of Internal Medicine, Laikon General Hospital, Medical School, University of Athens, Athens, 11527, Greece
| | - L Marinos
- Hemopathology Department, "Evangelismos" General Hospital, Athens, 10676, Greece
| | - A Economidi
- Dermatology Department, Cutaneous Lymphoma Clinic, Medical School, "A. Sygros" Hospital for Skin Diseases, National & Kapodestrian University of Athens, Athens, 16121, Greece
| | - P Panayiotidis
- Hematology Unit, 1st Propedeutic Department of Internal Medicine, Laikon General Hospital, Medical School, University of Athens, Athens, 11527, Greece
| | - D Rigopoulos
- Dermatology Department, Cutaneous Lymphoma Clinic, Medical School, "A. Sygros" Hospital for Skin Diseases, National & Kapodestrian University of Athens, Athens, 16121, Greece
| | - A J Stratigos
- Dermatology Department, Cutaneous Lymphoma Clinic, Medical School, "A. Sygros" Hospital for Skin Diseases, National & Kapodestrian University of Athens, Athens, 16121, Greece
| |
Collapse
|
9
|
Nikolaou V, Marinos L, Moustou E, Papadavid E, Economidi A, Christofidou E, Gerochristou M, Tasidou A, Economaki E, Stratigos A, Antoniou C. Psoriasis in patients with mycosis fungoides: a clinicopathological study of 25 patients. J Eur Acad Dermatol Venereol 2017; 31:1848-1852. [DOI: 10.1111/jdv.14365] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2017] [Accepted: 03/27/2017] [Indexed: 01/26/2023]
Affiliation(s)
- V. Nikolaou
- Cutaneous Lymphoma Clinic; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| | - L. Marinos
- Hemopathology Department; “Evangelismos Hospital”; Athens Greece
| | - E. Moustou
- Cutaneous Lymphoma Clinic; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| | - E. Papadavid
- Cutaneous Lymphoma Clinic; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| | - A. Economidi
- Cutaneous Lymphoma Clinic; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| | - E. Christofidou
- Pathology Department; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| | - M. Gerochristou
- Cutaneous Lymphoma Clinic; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| | - A. Tasidou
- Hemopathology Department; “Evangelismos Hospital”; Athens Greece
| | - E. Economaki
- Hemopathology Department; “Evangelismos Hospital”; Athens Greece
| | - A. Stratigos
- Cutaneous Lymphoma Clinic; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| | - C. Antoniou
- Cutaneous Lymphoma Clinic; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| |
Collapse
|
10
|
Nikolaou V, Papadavid E, Patsatsi A, Siakantaris M, Economidi A, Marinos L, Koletsa T, Georgiou E, Pappa V, Stratigos A, Antoniou C. Prognostic indicators for mycosis fungoides in a Greek population. Br J Dermatol 2017; 176:1321-1330. [DOI: 10.1111/bjd.15000] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/20/2016] [Indexed: 12/12/2022]
Affiliation(s)
- V. Nikolaou
- National and Kapodistrian University of Athens; Medical School; Athens Greece
| | - E. Papadavid
- National and Kapodistrian University of Athens; Medical School; Athens Greece
| | - A. Patsatsi
- Aristotle University School of Medicine; Thessaloniki Greece
| | - M. Siakantaris
- National and Kapodistrian University of Athens; Medical School; Athens Greece
| | - A. Economidi
- National and Kapodistrian University of Athens; Medical School; Athens Greece
| | - L. Marinos
- Department of Hemopathology; Evangelismos Hospital; Athens Greece
| | - T. Koletsa
- Aristotle University School of Medicine; Thessaloniki Greece
| | - E. Georgiou
- Aristotle University School of Medicine; Thessaloniki Greece
| | - V. Pappa
- National and Kapodistrian University of Athens; Medical School; Athens Greece
| | - A. Stratigos
- National and Kapodistrian University of Athens; Medical School; Athens Greece
| | - C. Antoniou
- National and Kapodistrian University of Athens; Medical School; Athens Greece
| |
Collapse
|
11
|
Nikolaou V, Papadavid E, Economidi A, Marinos L, Moustou E, Karampidou K, Papadaki T, Stratigos A, Antoniou C. Mycosis fungoides in the era of antitumour necrosis factor-α treatments. Br J Dermatol 2015; 173:590-3. [PMID: 25639382 DOI: 10.1111/bjd.13705] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- V Nikolaou
- Lymphoma Clinic, 'A. Sygros' Hospital for Skin Diseases, 5 I. Dragoumi Str., 16121, Athens, Greece.
| | - E Papadavid
- Lymphoma Clinic, 'A. Sygros' Hospital for Skin Diseases, 5 I. Dragoumi Str., 16121, Athens, Greece
| | - A Economidi
- Lymphoma Clinic, 'A. Sygros' Hospital for Skin Diseases, 5 I. Dragoumi Str., 16121, Athens, Greece
| | - L Marinos
- Hemopathology Department, 'Evagelismos' Hospital, Athens, Greece
| | - E Moustou
- Psoriasis Clinic, 'A. Sygros' Hospital for Skin Diseases, 5 I. Dragoumi Str., 16121, Athens, Greece
| | - K Karampidou
- Lymphoma Clinic, 'A. Sygros' Hospital for Skin Diseases, 5 I. Dragoumi Str., 16121, Athens, Greece
| | - T Papadaki
- Hemopathology Department, 'Evagelismos' Hospital, Athens, Greece
| | - A Stratigos
- Lymphoma Clinic, 'A. Sygros' Hospital for Skin Diseases, 5 I. Dragoumi Str., 16121, Athens, Greece.,Psoriasis Clinic, 'A. Sygros' Hospital for Skin Diseases, 5 I. Dragoumi Str., 16121, Athens, Greece
| | - C Antoniou
- Lymphoma Clinic, 'A. Sygros' Hospital for Skin Diseases, 5 I. Dragoumi Str., 16121, Athens, Greece.,Psoriasis Clinic, 'A. Sygros' Hospital for Skin Diseases, 5 I. Dragoumi Str., 16121, Athens, Greece
| |
Collapse
|
12
|
Nikolaou V, Siakantaris MP, Vassilakopoulos TP, Papadavid E, Stratigos A, Economidi A, Marinos L, Papadaki T, Antoniou C. PUVA plus interferon α2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series. J Eur Acad Dermatol Venereol 2011; 25:354-7. [DOI: 10.1111/j.1468-3083.2010.03732.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
13
|
Nikolaou VA, Papadavid E, Katsambas A, Stratigos AJ, Marinos L, Anagnostou D, Antoniou C. Clinical characteristics and course of CD8+ cytotoxic variant of mycosis fungoides: a case series of seven patients. Br J Dermatol 2009; 161:826-30. [PMID: 19558552 DOI: 10.1111/j.1365-2133.2009.09301.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND Fewer than 5% of cases of mycosis fungoides (MF) present with a cytotoxic/suppressor CD8+ phenotype which, despite immunophenotypic similarities with CD8+ aggressive lymphomas, is regarded as a phenotypic variant of MF. Poikilodermatous MF showing a CD8+ phenotype has been reported to have a nonaggressive clinical behaviour and a good response to psoralen plus ultraviolet A treatment. OBJECTIVES To perform a retrospective study of CD8+ MF cases diagnosed in the skin lymphoma clinic of Andreas Sygros Hospital. METHODS We analysed the clinical characteristics, the immunophenotypic and molecular indices, as well as the clinical course of these patients. RESULTS Seven cases of CD8+ MF (6.5% of all cases of cutaneous T-cell lymphoma) were diagnosed during 2002-2007. One of seven patients had stage IA, five stage IB and one stage IIB disease. Clinical characteristics were variable: four of seven patients presented with poikilodermatous plaques (in one of them lesions of lymphomatoid papulosis with CD8+ phenotype coexisted), one patient with classic MF, one with plantar MF and one with follicular MF. The time period between disease onset and diagnosis was long for most patients (up to 33 years). All patients received the recommended treatment according to TNM staging. Five of seven patients had complete remission, one partial response and one stable disease. CONCLUSIONS Special clinical characteristics, such as hyperpigmentation and poikiloderma, are often noted in CD8+ MF cases. In our series CD8+ MF presented with a long-standing disease and indolent course suggesting that CD8+ cytotoxic immunophenotype may represent a marker of mild biological behaviour.
Collapse
Affiliation(s)
- V A Nikolaou
- Dermatology Department, Andreas Sygros Hospital, University of Athens, Athens 17456, Greece.
| | | | | | | | | | | | | |
Collapse
|
14
|
Marinos L, Economaki E, Stavroyianni N, Papadaki C, Xylouri I, Lalayanni C, Paterakis G, Pouliou E, Athanasiadou A, Kokkini G, Papadaki H, Fassas A, Anagnostopoulos A, Stamatopoulos K, Papadaki T. P082 Hematological manifestations and histopathological findings in T-large granular lymphocyte leukemia. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70162-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Agalias A, Mihopoulos N, Tsoukatou M, Marinos L, Vagias C, Harvala C, Roussis V. New prostaglandins from the chemically defended soft coral Plexaura nina. Z NATURFORSCH C 2000; 55:425-30. [PMID: 10928555 DOI: 10.1515/znc-2000-5-619] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Three new prostaglandins were isolated as minor constituents of the organic extract from the Caribbean soft coral Plexaura nina. The structures of the new natural products were established by means of spectral data analysis, including 2D NMR experiments. The unpalatability of the lipid extract of the coral and the defensive role of the major prostaglandin metabolites were determined by laboratory and field fish-feeding assays.
Collapse
Affiliation(s)
- A Agalias
- School of Pharmacy, Department of Pharmacognosy, University of Athens, Greece
| | | | | | | | | | | | | |
Collapse
|